What is EdenRx and what does it offer?

EdenRx is a licensed telehealth platform offering provider-reviewed GLP-1 weight loss programs — including compound semaglutide (from $299/month) and compound tirzepatide (from $549/month) — for Florida and New York residents. No clinic visits required. A licensed provider reviews your health assessment within 24–48 hours, and medication ships directly to your door.

What are GLP-1 medications and how do they work?

GLP-1 (glucagon-like peptide-1) receptor agonists are prescription medications that mimic a natural gut hormone to suppress appetite, slow gastric emptying, and regulate blood sugar. Semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) are the most clinically proven GLP-1 medications, producing 15–22% average body weight loss in clinical trials.

How much does semaglutide cost in Florida?

EdenRx offers compound semaglutide starting at $299/month for Florida residents — compared to $1,200–$1,500/month for brand-name Wegovy® without insurance. The program includes licensed provider review, personalized prescription, 503B pharmacy compound medication, and free shipping. No insurance required. Only pay if approved.

How much does tirzepatide cost in New York?

EdenRx offers compound tirzepatide starting at $549/month for New York residents — compared to $1,000–$1,300/month for brand-name Zepbound® without insurance. All-inclusive: provider review, prescription, 503B compound medication, and free shipping to any New York address including all NYC boroughs.

Do I need to visit a clinic for GLP-1 treatment?

No. EdenRx is 100% online. Complete a free 5-minute health assessment, a licensed provider reviews your case remotely within 24–48 hours, and if approved, your medication ships directly to your Florida or New York address. No in-person visits or appointments required.

How much weight can I lose with semaglutide or tirzepatide?

Clinical trial data: semaglutide produces an average of 14.9% body weight loss over 68 weeks (STEP-1 trial, NEJM 2021). Tirzepatide produces up to 20.9% average body weight loss over 72 weeks (SURMOUNT-1 trial, NEJM 2022). For a 200-lb patient: ~30 lbs (semaglutide) to ~42 lbs (tirzepatide). Individual results vary.

What is compound semaglutide vs Ozempic or Wegovy?

Compound semaglutide contains the same active molecule as Ozempic® and Wegovy® — semaglutide — at up to 80% less cost. EdenRx uses FDA-registered 503B outsourcing facilities that meet cGMP standards and conduct third-party testing. Compound semaglutide: from $299/month vs. Wegovy® at $1,200–$1,500/month.

Who qualifies for GLP-1 weight loss treatment?

You may qualify if you have a BMI ≥ 30 (obesity), or a BMI ≥ 27 with at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or sleep apnea. Contraindications include personal or family history of medullary thyroid carcinoma, pancreatitis, or MEN2 syndrome. Complete EdenRx's free assessment to find out if you qualify.

Is EdenRx available in New York City?

Yes. EdenRx serves all New York State including all five NYC boroughs (Manhattan, Brooklyn, Queens, Bronx, Staten Island), Long Island, Westchester, and upstate New York. Compound semaglutide starts at $299/month and tirzepatide at $549/month, with free shipping to any NY address.

What is the best Ozempic or Wegovy alternative?

Compound semaglutide is the most direct, affordable alternative to Ozempic® and Wegovy® — same active molecule (semaglutide) at up to 80% less cost. EdenRx offers compound semaglutide from $299/month vs. $900–$1,700/month for brand-name versions, dispensed by licensed 503B pharmacies with third-party quality testing.

What percentage of American adults are overweight?

According to the CDC, more than 70% of American adults are overweight or obese based on BMI criteria. Obesity (BMI ≥30) affects approximately 42% of adults. These figures represent one of the most significant public health challenges in modern medicine.

How effective is medical weight loss compared to diet alone?

Clinical trials consistently show that medically supervised programs — including GLP-1 receptor agonists alongside lifestyle intervention — produce significantly greater average weight loss than lifestyle modification alone. However, individual outcomes vary and no result is guaranteed.

What is a clinically significant amount of weight loss?

Medical guidelines generally consider 5–10% reduction in body weight clinically meaningful, as it is associated with improvements in blood pressure, blood sugar, and other cardiometabolic markers. This is used as a benchmark in clinical trials.

How does GLP-1 compare to older weight loss medications?

GLP-1 receptor agonists have generally demonstrated greater average weight loss in clinical trials than older pharmacological approaches. However, direct comparisons are complex due to different study designs and patient populations.

Why do most diets fail long-term?

Research indicates that weight regain after diet-only interventions is extremely common. Hormonal adaptations — including changes in ghrelin and leptin — create biological pressure to regain weight. This is part of why medication-assisted approaches under provider supervision have gained clinical attention.

Evidence-Based · Peer-Reviewed Sources

Weight Loss & Obesity Statistics

A data-driven reference on obesity prevalence, clinical trial outcomes for GLP-1 receptor agonists, and the public health landscape of weight management in the United States. All statistics sourced from peer-reviewed publications and government data.

Start Free Medical Assessment Read the GLP-1 Guide

Statistics are for educational reference only. Individual outcomes vary. Provider approval required for treatment.

HIPAA Secure Intake Provider-Reviewed 6,000+ Patients Served Decision Within 24h Licensed Pharmacies Delivered to Your Door

Key Statistics at a Glance

The following figures are drawn from government data, peer-reviewed journals, and major clinical trial programs. Group averages from clinical trials do not predict individual outcomes.

42%

of American adults have obesity (BMI ≥30)

CDC, National Center for Health Statistics, 2024

71%

of American adults are overweight or obese

CDC NHANES Data

~15%

mean body weight reduction in STEP 1 semaglutide trial (group average)

Wilding et al., NEJM 2021

~22%

mean body weight reduction in SURMOUNT-1 tirzepatide trial (highest dose, group average)

Jastreboff et al., NEJM 2022

$173B

estimated annual cost of obesity-related healthcare in the US

CDC, 2019 estimate

80%+

of participants achieved ≥5% weight loss with GLP-1 treatment in major trials

STEP & SURMOUNT trial programs

5–10%

weight loss threshold considered clinically meaningful by medical guidelines

American Society for Metabolic and Bariatric Surgery

66%

weight regain observed within 1 year of stopping GLP-1 treatment (STEP 4 data)

Davies et al., The Lancet 2021

All statistics represent population-level or group-average data from cited sources. They do not predict, imply, or guarantee any individual outcome. Treatment results vary significantly by person.

Obesity Prevalence in the United States

Obesity is now classified as a chronic disease by the American Medical Association, the World Health Organization, and major medical bodies. The prevalence has more than tripled since the 1980s, driven by complex interplays of environment, genetics, and metabolic biology.

Adults with overweight (BMI 25–29.9)

CDC NHANES, most recent cycle

30%

Adults with obesity (BMI 30–39.9)

CDC NHANES, most recent cycle

32%

Adults with severe obesity (BMI ≥40)

CDC NHANES, most recent cycle

10%

Children aged 2–19 with obesity

CDC, 2024

19.7%

Adults who have ever tried to lose weight

National surveys, CDC

~50%

GLP-1 Clinical Trial Outcome Data

The following summarizes weight loss outcome data from major randomized controlled trials. All figures represent group averages and include placebo comparisons where available. These numbers represent what trial participants experienced on average — not what any individual will experience.

Trial	Medication	Duration	Mean Weight Loss (Treatment)	Mean Weight Loss (Placebo)
STEP 1	Semaglutide 2.4mg	68 weeks	~15%	~2.4%
STEP 2	Semaglutide 2.4mg (T2D)	68 weeks	~10%	~3%
STEP 3	Semaglutide + intensive behavioral	68 weeks	~16%	~5.7%
STEP 4	Semaglutide (continuation)	48 weeks ext.	Maintained	~+7% regain
SURMOUNT-1	Tirzepatide 15mg	72 weeks	~22%	~2%
SURMOUNT-2	Tirzepatide (T2D)	72 weeks	~15%	~3%

All data from published peer-reviewed trials. Group averages do not predict individual results. Results vary significantly. Sources: NEJM, The Lancet.

Why These Statistics Matter for Patients

Understanding the clinical data landscape helps patients make informed decisions in conversation with their providers. There are several key takeaways from the data that are relevant to anyone considering medical weight loss:

Weight loss is biologically complex

Obesity research has increasingly established that weight is regulated by a complex hormonal system. This is why willpower-based approaches alone often show limited long-term success in clinical studies.

Results vary significantly

Clinical trials report group averages. Some participants lose much more, others much less. No trial result should be interpreted as a personal prediction.

Treatment continuation matters

STEP 4 data showed significant weight regain after stopping treatment, suggesting that ongoing care and provider monitoring are important components of sustained outcomes.

Provider oversight is essential

All major trials included medical oversight, dose titration, and monitoring. This is why EdenRx's provider-reviewed model is central to how we operate — not a marketing claim.

Provider-reviewed GLP-1 programs in FL & NY

No payment required to start · Licensed providers · Only pay if approved

Start Free Assessment Explore Wellness Programs

Provider-reviewed · Only pay if approved · Cancel anytime